

April 5, 2024

Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Symbol: MAXHEALTH

Listing Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 543220

Sub.: Postal Ballot Notice

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please find enclosed postal ballot notice dated March 19, 2024 along with the explanatory statement thereto (“Notice”), sent to members of the Company seeking their approval by way of remote e-voting (“E-voting”) to transact following special businesses:

S. No.	Type of Resolution	Description of Resolution
1.	Special Resolution	Re-appointment of Mr. Michael Thomas Neeb as an Independent Director of the Company
2.	Special Resolution	Re-appointment of Mr. Mahendra Gumanmalji Lodha as an Independent Director of the Company

In accordance with relevant circulars of Ministry of Corporate Affairs, the Company has completed the dispatch of Notice to its members today i.e. April 5, 2024 at 6.30 pm (IST), only through e-mail whose names appear in the register of members of the Company and/ or in the register of beneficial owners maintained by the depositories as on Friday, March 29, 2024 (“Cut-off Date”). Members holding shares as on Cut-off Date are entitled to vote on the resolutions as mentioned in the Notice.

The Company has engaged the services of Link Intime India Private Limited, its registrar and share transfer agent, for facilitating E-voting. The detailed procedure with respect to E-voting is mentioned in Notes to the Notice.

Key information pertaining to postal ballot is as under:

S. No.	Particulars	Details
1.	E-voting starts at	9.00 am (IST) on Saturday, April 6, 2024
2.	E-voting ends at	5.00 pm (IST) on Sunday, May 5, 2024
3.	Results of postal ballot	on or before Tuesday, May 7, 2024



This disclosure will also be hosted on Company's website viz. www.maxhealthcare.in.

Kindly take the same on record.

Thanking you

Yours truly,
For **Max Healthcare Institute Limited**

Dhiraj Arora
SVP - Company Secretary and Compliance Officer

Encl.: As above



Max Healthcare Institute Limited
Postal Ballot Notice



Postal Ballot Notice

Information at a Glance

Particulars	Details
Mode of voting on Postal Ballot	Remote E-voting
Event no. for Postal Ballot	240144
Cut-off for E-voting	Friday, March 29, 2024
E-voting starts	Saturday, April 6, 2024, 9:00 am (IST) onwards
E-voting ends	Sunday, May 5, 2024, 5:00 pm (IST)
E-voting website	https://instavote.linkintime.co.in
Name, address and contact details of registrar and share transfer agent/ e-voting service provider	Contact Person: Mr. Swapan Naskar Associate Vice President & Head (North India)
	Address: Link Intime India Private Limited Noble Heights, 1 st Floor, C-1 Block, Near Savitri Market, Janakpuri, New Delhi- 110 058, Delhi, India Telephone No.: +91-11-4941-1000 E-mail: enotices@linkintime.co.in ; rnt.helpdesk@linkintime.co.in
Company Contact Details	Contact Person: Mr. Dhiraj Arora SVP - Company Secretary & Compliance Officer
	Address: Max Healthcare Institute Limited 2 nd Floor, Capital Cyberscape, Sector-59, Gurugram- 122 102, Haryana, India Telephone No.: +91-124-620 7777 Mobile: +91- 987333 6660 E-mail: investors@maxhealthcare.com
Name and E-mail address of the Scrutinizer	Name: DPV & Associates LLP E-mail: dpv@dpvassociates.com



Max Healthcare Institute Limited

CIN: L72200MH2001PLC322854

Registered Office: 401, 4th Floor, Man Excellenza, S. V. Road, Vile Parle (West), Mumbai – 400 056, Maharashtra, India

Corporate Office: 2nd Floor, Capital Cyberscape, Sector-59, Gurugram – 122 102, Haryana, India

E-mail: investors@maxhealthcare.com; **Website:** www.maxhealthcare.in

Telephone No.: +91-22 2610 0461/62; +91-124-620 7777

Postal Ballot Notice

Dear Members,

Notice is hereby given pursuant to the provisions of section 110 read with section 108 and all other applicable provisions, if any, of the Companies Act, 2013 (“Act”) read with rule 20 and 22 of the Companies (Management and Administration) Rules, 2014 and other applicable rules, if any (“Rules”), regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), Secretarial Standard on General Meetings (“SS-2”) issued by the Institute of Company Secretaries of India (“ICSI”), including any statutory modification(s), clarification(s), substitution(s) or re-enactment(s) thereof for the time being in force and framework prescribed by the Ministry of Corporate Affairs (“MCA”) vide general circular nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020 read with other relevant circulars, including latest being general circular no. 9/2023 dated September 25, 2023 (collectively referred to as “MCA Circulars”) and any other applicable laws, rules and regulations for the time being in force, that the special resolutions set forth herein below, are proposed to be passed by the members of Max Healthcare Institute Limited (“Company”) through postal ballot, **only by way of remote e-voting (“E-voting”)**.

In accordance with the MCA Circulars, the postal ballot notice (“**Notice**”) along with explanatory statement is being sent only through electronic mode to those members whose e-mail address are registered with the Company or its registrar & share transfer agent or depository(ies) and whose names appear in the register of members of the Company and/ or in the register of beneficial owners maintained by the depositories as on **Friday, March 29, 2024 (“Cut-off Date”)**. The communication of the assent or dissent of the members would take place through E-voting only.

In compliance with the provisions of section 108 and 110 of the Act read with Rules, regulation 44 of the SEBI Listing Regulations and SS-2, the Company is providing E-voting facility to its members, to enable them to cast their vote electronically. The

Company has engaged the services of Link Intime India Private Limited (“RTA”) for facilitating E-voting. The detailed procedure with respect to E-voting is mentioned in ‘Notes’ to the Notice.

The E-voting schedule is as follows:

E-voting Starts on	E-voting Ends on
Saturday, April 6, 2024 9:00 am (IST) onwards	Sunday, May 5, 2024 5:00 pm (IST)

Members are requested to cast their vote through E-voting at any time before Sunday, May 5, 2024, 5:00 pm (IST) (i.e. last date to cast vote electronically). E-voting module shall be disabled thereafter. Members are requested to carefully read the instructions and follow the procedure with respect to E-voting as stated in the ‘Notes’ forming part of the Notice.

The Notice shall also be uploaded on the website of the Company at www.maxhealthcare.in/investors and on the E-voting website of RTA at <https://instavote.linkintime.co.in>. The Notice can also be accessed from the website of stock exchanges i.e. National Stock Exchange of India Limited (“NSE”) at www.nseindia.com and BSE Limited (“BSE”) at www.bseindia.com.

The board of directors of the Company (“Board”) has appointed Mr. Devesh Kumar Vasisht (ICSI Membership No. F8488) or failing him, Mr. Parveen Kumar (ICSI Membership No. F10315), Partners of DPV & Associates LLP, Practicing Company Secretaries, Delhi, as the scrutinizer for conducting the postal ballot through E-voting process in a fair and transparent manner.

The scrutinizer will submit his report, after the completion of scrutiny of the votes cast, to the Chairman and Managing Director of the Company or any person authorized by him. **The results of E-voting will be announced on or before Tuesday, May 7, 2024.**

The statement pursuant to section 102 and 110 of the Act setting out the material facts relating to the resolutions is annexed to the Notice.

Special Business

1. Re-appointment of Mr. Michael Thomas Neeb as an Independent Director of the Company

To consider and if thought fit, to pass the following resolution as a **Special Resolution**:

“Resolved That pursuant to the provisions of section 149, 152 read with schedule IV and all other applicable provisions, if any, of the Companies Act, 2013 (“Act”), the rules framed thereunder including the Companies (Appointment and Qualification of Directors) Rules, 2014, regulation 17 and all other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), relevant circulars issued by BSE Limited and National Stock Exchange of India Limited, the articles of association of the Company, nomination, remuneration and board diversity policy of the Company and based on recommendation of the Nomination and Remuneration Committee and the board of directors of the Company (“Board”), Mr. Michael Thomas Neeb (DIN: 08522685), who holds the office as an Independent Director of the Company and who meets the criteria for independence as prescribed under the Act and SEBI Listing Regulations, and being eligible for re-appointment as an Independent Director, and in respect of whom the Company has received a notice in writing under section 160(1) of the Act from a member proposing his candidature for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, for a second term effective from June 21, 2024 to June 20, 2029 (both days inclusive).

Resolved Further That the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things as the Board may in its absolute discretion deem necessary, desirable or expedient, including but not limited to filing forms, applications and making representations, seeking all necessary approvals from relevant authorities, including governmental authorities, if any, to give effect to this resolution, for and on behalf of the Company and settling all such issues, questions, difficulties or doubts whatsoever that may arise without being required to seek further consent or approval of the members or otherwise to the end and intent that the members shall be deemed to have given their approval thereto expressly by the authority of this resolution and to delegate all or any of the powers conferred herein to director(s), committee(s), executive(s), officer(s) or representative(s) of the Company or to any other person, to do all such acts, deeds, matters and things as may be considered necessary and/or expedient and to

execute such documents, writings etc. as may be necessary to give effect to forgoing resolution.”

2. Re-appointment of Mr. Mahendra Gumanmalji Lodha as an Independent Director of the Company

To consider and if thought fit, pass the following resolution as a **Special Resolution**:

“Resolved That pursuant to the provisions of section 149, 152 read with schedule IV and all other applicable provisions, if any, of the Companies Act, 2013 (“Act”), the rules framed thereunder including the Companies (Appointment and Qualification of Directors) Rules, 2014, regulation 17 and all other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), relevant circulars issued by BSE Limited and National Stock Exchange of India Limited, the articles of association of the Company, nomination, remuneration and board diversity policy of the Company and based on recommendation of the Nomination and Remuneration Committee and the board of directors of the Company (“Board”), Mr. Mahendra Gumanmalji Lodha (DIN: 00012920), who holds the office as an Independent Director of the Company and who meets the criteria for independence as prescribed under the Act and SEBI Listing Regulations, and being eligible for re-appointment as an Independent Director, and in respect of whom the Company has received a notice in writing under section 160(1) of the Act from a member proposing his candidature for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, for a second term effective from June 21, 2024 to June 20, 2029 (both days inclusive).

Resolved Further That the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things as the Board may in its absolute discretion deem necessary, desirable or expedient, including but not limited to filing forms, applications and making representations, seeking all necessary approvals from relevant authorities, including governmental authorities, if any, to give effect to this resolution, for and on behalf of the Company and settling all such issues, questions, difficulties or doubts whatsoever that may arise without being required to seek further consent or approval of the members or otherwise to the end and intent that the members shall be deemed to have given their approval thereto expressly by the authority of this resolution and to delegate all or any of the powers conferred herein to director(s), committee(s), executive(s), officer(s) or representative(s) of the Company or to any other person, to do all such acts, deeds, matters and things as may be considered necessary and/or expedient and to execute such documents, writings etc. as may be necessary to give effect to forgoing resolution.”

Registered Office

401, 4th Floor, Man Excellenza,
S. V. Road, Vile Parle (West),
Mumbai - 400 056, Maharashtra

By order of the Board of Directors
For **Max Healthcare Institute Limited**

Dhiraj Arora
SVP - Company Secretary & Compliance Officer

Membership No.: A28079

March 19, 2024
Gurugram

Notes:

1. The explanatory statement pursuant to section 102 of the Act read with the Rules, setting out material facts concerning the business under resolution no. 1 and 2 of the accompanying Notice, is annexed hereto. Relevant details of directors proposed to be re-appointed as required under regulation 36(3) of the SEBI Listing Regulations and SS-2 are also provided in the explanatory statement.
2. The Notice along with explanatory statement and E-voting instructions are being sent **only through electronic mode** to members whose e-mail address are registered with the Company or its registrar & share transfer agent or depository(ies) and whose names appear in the register of members of the Company and/ or in the register of beneficial owners maintained by the Depositories as on **Friday, 29 March, 2024 ("Cut-off Date")**. A person who is not a member as on the Cut-off Date should treat the Notice for information purpose only.

Members may note that the Notice shall also be uploaded on the website of the Company at www.maxhealthcare.in/investors, on the website of RTA at <https://instavote.linkintime.co.in>. The Notice can also be accessed from the websites of stock exchanges i.e. NSE at www.nseindia.com and BSE at www.bseindia.com.
3. In accordance with framework provided under MCA Circulars, physical copy of the Notice along with postal ballot forms and pre-paid business envelope will not be sent to members and accordingly, members are required to communicate their assent or dissent only through E-voting.
4. The Board of the Company has appointed Mr. Devesh Kumar Vasisht (ICSI Membership No. F8488) or failing him, Mr. Parveen Kumar (ICSI Membership No. F10315), Partners of DPV & Associates LLP, Practicing Company Secretaries, Delhi, as the scrutinizer for conducting the postal ballot only through E-voting process in a fair and transparent manner, who has communicated willingness to be appointed for the said purpose.
5. The scrutinizer's decision on the validity of the postal ballot through E-voting shall be final. Upon completion of scrutiny of the votes, the scrutinizer shall submit his report to the Chairman and Managing Director or any person authorized by him. The results of the postal ballot will be announced by the Chairman and Managing Director or any person authorized by him in writing for this purpose on or before **Tuesday, May 7, 2024** at the registered office of the Company. The said results along with scrutinizer's report would be communicated to the stock exchanges and also be displayed at the registered and corporate office of the Company. Additionally, the said results will also be uploaded on the website of the Company viz. www.maxhealthcare.in as well as on the website of the RTA viz. <https://instavote.linkintime.co.in>.
6. The resolution(s), if passed by requisite majority, shall be deemed to have been passed on the last date specified by the Company for E-voting i.e. **Sunday, May 5, 2024**. Further, resolution(s) passed by members through postal ballot are deemed to have been passed as if they are passed at a general meeting of members.
7. All material documents referred in the Notice and explanatory statement will be available for inspection without any fee by members of the Company at the registered office of the Company during office hours on working days from the date of dispatch of the Notice until the last date for receipt of votes by E-voting. Alternatively, members may inspect documents electronically, without any fee, by sending e-mail at investors@maxhealthcare.com from their registered e-mail address mentioning their name, folio number/DP ID and Client ID.
8. SEBI has mandated the submission of PAN, KYC details and nomination by holders of physical securities and linking PAN with Aadhaar vide its circulars dated March 16, 2023, and November 17, 2023. Members are requested to submit their PAN, KYC and nomination details to the Company's RTA at rnt.helpdesk@linkintime.co.in. The forms for updating the same are available at linkintime.co.in/client-downloads.html. Members holding shares in dematerialised form are requested to submit their PAN to their depository participant(s).
9. In accordance with the MCA Circulars, members are requested to take note of the following:

Members holding shares of the Company in dematerialised form can verify/update their e-mail address and mobile numbers with their respective depository participant(s). Members can also temporarily update their e-mail address and mobile number with RTA, by following the procedure given below:

 - a) Visit the link: https://linkintime.co.in/emailreg/email_register.html and follow the registration process as guided thereafter. Post successful registration of the e-mail address, the members would get soft copy of the Notice along with the User-ID and the password to cast vote. In case of any queries, members may write to the Company at investors@maxhealthcare.com or to RTA at rnt.helpdesk@linkintime.co.in;
 - b) It is clarified that for permanent registration of e-mail address, members are however requested to register their e-mail address, in respect of dematerialised holdings with the depository(ies) through the concerned depository participant(s), by following the due procedure; and
 - c) Those members who have already registered their e-mail address are requested to keep their e-mail address validated with their depository participant(s) / the Company's RTA, to enable servicing of notices / documents / Annual Reports electronically to their e-mail address.

10. We urge members to support our commitment to environmental protection by choosing to receive the Company's communication through e-mail. Members holding shares in Demat mode, and who have not registered their e-mail address are requested to register their e-mail address and bank account details in demat account, as per the process advised by their respective depository participant(s).
11. In case members have any queries or issues regarding remote E-voting, they may refer the (i) Frequently Asked Questions ("FAQs"); or (ii) Instavote E-voting manual, available under Help section at <https://instavote.linkintime.co.in>, or contact Mr. Swapan Naskar, Associate Vice President & Head (North India), Link Intime India Private Limited, Noble Heights, 1st Floor, C-1 Block, Near Savitri Market, Janak Puri, New Delhi -110058 or Call at 011- 49411000 or write an e-mail to enotices@linkintime.co.in.

E-VOTING:

1. In compliance with regulation 44 of the SEBI Listing Regulations and section 108 and 110 of the Act read with the Rules, as amended, SS-2 and MCA Circulars, the Company is pleased to provide E-voting facility for its members to enable them to cast their vote electronically through E-voting services provided by RTA in respect of the resolutions as set out in the Notice. Instructions for E-voting are provided in this notice.
 2. The E-voting period commences from **Saturday, April 6, 2024 at 9:00 am (IST)** onwards and ends on **Sunday, May 5, 2024 at 5:00 pm (IST)** (both days inclusive). During this period, members of the Company holding equity shares either in physical or dematerialized form as on the **Cut-off date, i.e. Friday, 29 March, 2024** (including those members who may not have received this Notice due to non-registration of their e-mail address with the Company or the depositories), may cast their vote electronically, in respect of the resolution(s) as set out in this Notice only through E-voting.
 3. The E-voting shall not be allowed beyond the aforesaid date and time and the E-voting module shall be forthwith disabled by RTA upon expiry of the aforesaid period. Once the vote on the resolution is cast by the member, he/she shall not be allowed to change it subsequently.
 4. The voting rights shall be reckoned in proportion to the paid-up equity shares registered in the name of member/beneficial owner as on the Cut-off date. A person, whose name is recorded in the register of members of the Company and/ or in the Register of Beneficial Owners maintained by the depository(ies) as on the cut-off date shall only be entitled to cast their vote through E-voting.
- directly with the depository(ies) or will have the option of accessing various e-voting service providers portals directly from their demat accounts.

Login method for Individual members holding securities in demat mode is given below:

1. Individual members holding securities in demat mode with NSDL
 - a) Existing IDeAS user can visit the e-Services website of NSDL viz. <https://eservices.nsdl.com> either on a personal computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see E-voting services under Value added services. Click on "Access to E-voting" under E-voting services and you will be able to see E-voting page. Click on company name or E-voting service provider name i.e. LINKINTIME and you will be re-directed to "InstaVote" website for casting your vote during the E-voting period.
 - b) If you are not registered for IDeAS e-Services, option to register is available at <https://eservices.nsdl.com> Select "Register Online for IDeAS Portal" or click at <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>.
 - c) Visit the E-voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com> either on a personal computer or on a mobile. Once the home page of E-voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see E-voting page. Click on company name or E-voting service provider name i.e. LINKINTIME and you will be redirected to "InstaVote" website for casting your vote during the E-voting period.
2. Individual members holding securities in demat mode with CDSL
 - a) Users who have opted for CDSL Easi/ Easiest facility, can login through their existing user id and password. The option will be made available to reach E-voting page without any further authentication. The users to login Easi/ Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then use your existing Myeasi username & password.
 - b) After successful login the Easi/ Easiest user will be able to see the E-voting option for eligible companies where the E-voting is in progress as per the information provided by the Company. On clicking the E-voting

E-Voting Instructions for Members:

As per the SEBI circular dated December 9, 2020, individual members holding securities in demat mode can register

option, the user will be able to see E-voting page of the E-voting service provider i.e. LINKINTIME for casting your vote during the remote E-voting period. Additionally, there are also links provided to access the system of all E-voting Service Providers, so that the user can visit the E-voting service providers' website directly.

- c) If the user is not registered for Easi/ Easiest, the option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option.
- d) Alternatively, the user can directly access the E-voting page by providing Demat Account Number and PAN Number from a E-voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & e-mail as recorded in the Demat Account. After successful authentication, the user will be able to see the E-voting option where the E-voting is in progress and also able to directly access the system of all E-voting Service Providers.

3. Individual members (holding securities in demat mode) can login through their depository participant(s)

You can also login using the login credentials of your demat account through your Depository participant(s) registered with NSDL/CDSL for E-voting facility. After Successful login, you will be able to see E-voting option. Once you click on E-voting option, you will be redirected to NSDL/CDSL, Depository site after successful authentication, wherein you can see E-voting feature. Click on the company name or E-voting service provider name i.e. LinkIntime and you will be redirected to E-voting service provider website for casting your vote during the remote E-voting period.

Login method for Individual members holding securities in physical form/ Non-Individual members holding securities in demat mode is given below:

Individual members of the Company, holding shares in physical form / Non-Individual members holding securities in demat mode as on the cut-off date for E-voting may register for E-voting facility of RTA as under:

1. Open the internet browser and launch the URL: <https://instavote.linkintime.co.in>
2. Click on “**Sign Up**” under ‘**SHAREHOLDER**’ tab and register with your following details: -
 - a) **User ID:** Members holding shares in physical form shall provide Event No + Folio Number registered with the Company. Members holding shares in NSDL demat account shall provide 8 Character DP ID followed by 8 Digit Client ID; Members holding shares in CDSL demat account shall provide 16 Digit Beneficiary ID.

- b) **PAN:** Enter your 10-digit Permanent Account Number (PAN), Members who have not updated their PAN with the depository participant(s)/ Company shall use the sequence number provided to you, if applicable.
- c) **DOB/DOI:** Enter the Date of Birth (DOB) / Date of Incorporation (DOI) (As recorded with your DP / Company - in DD/MM/YYYY format).
- d) **Bank Account Number:** Enter your Bank Account Number (last four digits), as recorded with your DP/ Company.

Notes:

- i. *Members holding shares in physical form but have not recorded ‘C’ and ‘D’, shall provide their Folio number in ‘D’ above*
 - ii. *Members holding shares with NSDL, shall provide ‘D’ above*
 - e) Set the password of your choice (The password should contain minimum 8 characters, at least one special character (@!#\$%&*), at least one numeral, at least one alphabet and at least one capital letter).
 - f) Click “**confirm**” (Your password is now generated).
3. Click on ‘**Login**’ under ‘**SHAREHOLDER**’ tab.
 4. Enter your User ID, Password and Image Verification (CAPTCHA) Code and click on ‘Submit’.

Cast your vote electronically:

1. After successful login, you will be able to see the notification for E-voting. Select ‘**View**’ icon.
2. E-voting page will appear.
3. Refer the Resolution description and cast your vote by selecting your desired option ‘**Favour / Against**’ (If you wish to view the entire Resolution details, click on the ‘**View Resolution**’ file link).
4. After selecting the desired option i.e. Favour / Against, click on ‘**Submit**’. A confirmation box will be displayed. If you wish to confirm your vote, click on ‘**Yes**’, else to change your vote, click on ‘No’ and accordingly modify your vote.

Guidelines for Institutional shareholders:

Institutional shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on the E-voting system of RTA at <https://instavote.linkintime.co.in> and register themselves as ‘Custodian / Mutual Fund / Corporate Body’. They are also required to upload a scanned certified true copy of the board resolution /authority letter/power of attorney etc. together with attested specimen signature of the duly authorised representative(s) in PDF format in the ‘Custodian / Mutual Fund / Corporate Body’ login for the Scrutinizer to verify the same.

Helpdesk for Individual members holding securities in physical form/ Institutional shareholders:

Members facing any technical issue in login may contact Link Intime INSTAVOTE helpdesk by sending a request at enotices@linkintime.co.in or contact on: - Tel: 022 – 4918 6000.

Helpdesk for Individual members holding securities in demat mode:

Individual members holding securities in demat mode may contact the respective helpdesk for any technical issues related to login through Depository i.e. **NSDL** and **CDSL**.

Login type	Helpdesk details
Individual members holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at: 022 - 4886 7000 and 022 - 2499 7000
Individual members holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

Individual members holding securities in physical form who has forgotten the password:

If an Individual members holding securities in physical form has forgotten the USER ID [Login ID] or Password or both then the member can use the “Forgot Password” option available on the E-voting website of Link Intime: <https://instavote.linkintime.co.in>

1. Click on ‘Login’ under ‘SHAREHOLDER’ tab and further Click ‘forgot password?’

2. Enter User ID, select Mode and Enter Image Verification code (CAPTCHA). Click on “SUBMIT”.

In case member is having valid e-mail address, Password will be sent to his / her registered e-mail address. Members can set the password of his/her choice by providing the information about the particulars of the Security Question and Answer, PAN, DOB/ DOI, Bank Account Number (last four digits) etc. as mentioned above. The password should contain minimum 8 characters, at least one special character (@!#\$%&*), at least one numeral, at least one alphabet and at least one capital letter.

User ID for members holding shares in physical form (i.e. Share Certificate): Your User ID is Event No + Folio Number registered with the Company

Individual members holding securities in demat mode with NSDL/ CDSL who has forgotten the password:

Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned depository(ies) / depository participant(s) website.

1. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
2. For shareholders/ members holding shares in physical form, the details can be used only for voting on the resolutions contained in this Notice.
3. During the voting period, shareholders/ members can login any number of time till they have voted on the resolution(s) for a particular “Event”.

Explanatory Statement

Item No. 1

The board of directors of the Company ("Board"), on the recommendation of the Nomination and Remuneration Committee ("NRC"), had appointed Mr. Michael Thomas Neeb as an additional director of the Company with effect from June 21, 2019. Subsequently, the members approved the appointment of Mr. Neeb as an Independent Director of the Company at extraordinary general meeting held on July 15, 2019, for a period of 5 (five) consecutive years.

In terms of section 149(11) of the Companies Act, 2013 ("Act"), an Independent Director may hold office for two consecutive terms

of up to 5 (five) years each. Further, as per section 149(10) of the Act read with Regulation 25(2A) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("SEBI Listing Regulations"), an Independent Director shall be eligible for re-appointment, for second term of up to 5 (five) consecutive years, on passing of a special resolution by members of the Company. Also, regulation 17(1C) of SEBI Listing Regulations, *inter-alia*, provides that the listed entity shall ensure that approval of shareholders for re-appointment of a person on the Board is taken at the next general meeting or within a time period of 3 (three) months from the date of appointment, whichever is earlier.

Board & Committee meetings attendance and brief profile of Mr. Neeb

Presently, Mr. Neeb is Chairman of ESG & Sustainability Committee and is also a member of Audit Committee of the Company.

During his current tenure as an Independent Director of the Company, he has contributed immensely to the Board and Committee deliberations. The attendance of Mr. Neeb at Board and Committee meetings since his appointment, is as follows:

Financial Year	Board Meeting			Audit Committee*			ESG & Sustainability Committee*		
	Total meetings held during tenure	Meetings attended	% of attendance	Total meetings held during tenure	Meetings attended	% of attendance	Total meetings held during tenure	Meetings attended	% of attendance
2023-24	8	7	87.50	8	7	87.50	3 [#]	3	100
2022-23	8	8	100	8	8	100	1	1	100
2021-22	8	8	100	7	7	100	1 [#]	1	100
2020-21	6	6	100	1 [#]	1	100			Not Applicable
2019-20	4	3	75			Not Applicable			Not Applicable

*The Board approved the following on October 29, 2023:

- Constitution of separate Risk Management Committee and consequential change in the nomenclature of 'Audit and Risk Management Committee' to 'Audit Committee'.
- Change in the nomenclature of 'Business Responsibility and Sustainability Committee' to 'ESG & Sustainability Committee'.

[#]The details of changes in the Committee(s) membership/ chairmanship of Mr. Neeb during this period, are as follows:

- Designated as chairman of ESG & Sustainability Committee w.e.f. October 29, 2023.
- Inducted as member of Business Responsibility & Sustainability Committee by the Board w.e.f. August 10, 2021.
- Inducted as member of Audit Committee w.e.f. February 11, 2021.

Brief profile:

"Mr. Neeb holds a Master's degree in Business Administration from the University of Dallas and Bachelor's degree in accounting from Baylor University. He is an American National and has over 30 years of experience in US and International healthcare industry. He has worked with Hospital Corporation of America ('HCA') for 28 years, where he served in various senior leadership roles and led HCA's International Operations as Chief Executive Officer for a period of 12 years before his retirement. HCA's UK operations have been recognised for its outstanding quality, which enabled it to attract patients from around the globe.

He began his healthcare career as director of finance and project for Harris Methodist affiliated hospitals in Fort Worth, Texas. He has also worked for accounting firms such as EY and Arthur Anderson LLP. He is also on the Board of Evergreen Executive Advisors LLC, Telemetrix RPM, Inc. and several not-for-profit organisations."

The profile of Mr. Neeb can also be accessed on Company's website viz. www.maxhealthcare.in/investors.

Proposal and rationale for re-appointment of Mr. Neeb

The Company follows a robust process for re-appointment of Board members. NRC oversees the succession planning, *inter-alia*, for the Board and thoroughly assesses various factors while considering re-appointment of Independent Director including background, expertise, skill set, experience, performance evaluation, educational & professional qualifications and personal achievements.

Further, the Board also deliberates on various factors including present composition of the Board to ensure optimum combination of executive and non-executive directors, tenure of the Board members, skill matrix, board diversity, time-commitment and statutory requirements.

During review process of succession planning on March 18, 2024, NRC, *inter-alia*, evaluated re-appointment of existing Independent Directors and considered the proposal for re-appointment of Mr. Neeb as an Independent Director on Company's Board.

With over three decades of experience in healthcare management and finance, Mr. Neeb holds a profound and deep understanding of the industry's intricacies and challenges. His exemplary leadership as CEO of HCA Healthcare UK is testament of his ability to drive operational excellence and strategic growth initiatives. Moreover, his tenure as CFO for HCA's international division and previous roles within HCA highlights his financial acumen and expertise in optimizing organizational performance. His global perspective enables him to provide strategic guidance to the Company amidst a rapidly changing environment in healthcare domain, driving alignment with industry trends and best international practices.

Mr. Neeb is deeply involved in Company's strategies/ goals and actively participates in Board and Committee meetings. As evident from the information provided above, he has maintained an excellent attendance record at Board and Committee meetings. In view of his rich and extensive experience, engagements with Mr. Neeb are meaningful and offers valuable mentorship to the Company's management team.

NRC, after taking into account the positive outcome of the performance evaluation of Mr. Neeb during his current term as an Independent Director and considering his skills, acumen, knowledge, time commitment to Company, experience in the healthcare sector, as well as his contribution to the Company's evolution as one of India's largest private healthcare providers, recommended his re-appointment to the Board for a second term effective from June 21, 2024 to June 20, 2029. NRC further noted that skills, expertise and competencies possessed by Mr. Neeb are in alignment with the skills and expertise, identified by the NRC and the Board, for the Directors of the Company.

The Board, at its meeting held on March 19, 2024, considered the recommendation of the NRC and comprehensive performance evaluation report of Mr. Neeb. The Board duly recognized Mr. Neeb's remarkable skills, deep understanding and rich experience in healthcare sector. In view of his contribution over years as an Independent Director of the Company, the Board believes that Mr. Neeb's continued association as an Independent Director would be of immense benefit during this pivotal phase of growth.

In order to comply with the requirements of the Act and SEBI Listing Regulations in letter & spirit, and as measure to uphold high standards on corporate governance, the Board concluded that the tenure (current and prospective) of all Independent Directors, including Mr. Neeb, should be considered from the date of their respective joining Board of the Company. In line with the above and subject to approval of members of the Company, the Board approved the reappointment of Mr. Neeb as an Independent Director of the Company for a second term of 5 (five) years up to June 20, 2029 i.e., the date when Mr. Neeb completes his 10 years association with the Company as Director. The re-appointment of Mr. Neeb is in accordance with the nomination, remuneration and board diversity policy of the Company.

Performance Evaluation

The Board, in consultation with NRC, had formulated a framework containing the criteria for performance evaluation of the entire Board, its Committees, Chairman and Individual Directors, including Independent Directors. NRC and Board while considering performance evaluation of Mr. Neeb, *inter-alia*, considered assessment of his independent judgement that contributes to Board's deliberations, strategy and performance, his understanding of Company's business and goals, confidentiality, adherence to legal obligations and Company's code of conduct along with his understanding of roles and responsibilities as an Independent Director.

The NRC and Board are of the opinion that Mr. Neeb possesses relevant expertise and experience and is independent of management and duly fulfils the conditions specified in the Act, Rules made there under and SEBI Listing Regulations for re-appointment as an Independent Director.

Remuneration

Mr. Neeb shall be entitled to remuneration of ₹35,00,000/- (Rupees Thirty-Five Lakh only) per annum (payable on monthly basis) as approved by the members of the Company in their 22nd Annual General Meeting held on September 27, 2023 or any other remuneration as may be approved by members of the Company, from time to time, on the recommendation of Board and NRC. The remuneration is in line with the existing remuneration being paid to all other Non-Executive Directors (including Independent Directors).

In addition to the aforesaid remuneration, Mr. Neeb shall also be entitled to sitting fees for attending meeting(s) of the Board or any Committee and reimbursement of the expenses for attending meetings of the Board and Committee thereof, as permissible under the Act and/or SEBI Listing Regulations.

Disclosures and confirmations

The Company has received the notice under section 160 of the Act from a member signifying candidature of Mr. Neeb for the office of directors of the Company.

The Company has also received following documents from Mr. Neeb:

- a) consent in writing to act as director in Form DIR-2;

- b) intimation in Form DIR-8 to the effect he is not disqualified from being re-appointed as a director in terms of section 164 of the Act;
- c) declaration to the effect that he meets the criteria of independence as provided under the Act and SEBI Listing Regulations;
- d) confirmation that he is neither disqualified nor debarred from holding the office of director under the Act or pursuant to any order issued by SEBI or any such other authority;
- e) confirmation that he is not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact his ability to discharge duties with an objective independent judgment and without any external influence; and
- f) confirmation that he is registered with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs in accordance with the Act.

The copy of draft letter for re-appointment of Mr. Neeb as an Independent Director setting out the terms and conditions is available for electronic inspection to the members. The members may follow the process for inspection of document as mentioned in 'Notes' section forming part of the Notice.

The details as required under the SEBI Listing Regulations and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India and all other applicable provisions are provided in **Annexure** to the explanatory statement.

The Board recommends the resolution as set out in item no. 1 for approval of the members as special resolution.

Except Mr. Neeb and his relatives to the extent of their shareholding, if any, in the Company, none of the other directors / key managerial personnel and their relatives are in any way, concerned or interested, financially or otherwise, in the said resolution.

Item No. 2

The board of directors of the Company ("Board"), on the recommendation of the Nomination and Remuneration Committee ("NRC"), had appointed Mr. Mahendra Gumanmalji Lodha as an additional director of the Company with effect from June 21, 2019. Subsequently, the members approved the re-appointment of Mr. Lodha as an Independent Director of the Company at extra-ordinary general meeting held on July 15, 2019 for a period of 5 (five) consecutive years.

In terms of section 149(11) of the Companies Act, 2013 ("Act"), an Independent Director may hold office for two consecutive terms of upto 5 (five) years each. Further, as per section 149(10) of the Act read with Regulation 25(2A) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("SEBI Listing Regulations"), an Independent Director shall be eligible for re-appointment, for second term of up to 5 (five) consecutive years, on passing of a special resolution by members of the Company. Also, regulation 17(1C) of SEBI Listing Regulations, *inter-alia*, provides that the listed entity shall ensure that approval of shareholders for re-appointment of a person on the Board is taken at the next general meeting or within a time period of 3 (three) months from the date of appointment, whichever is earlier.

Board & Committee meetings attendance and brief profile of Mr. Lodha

Presently, Mr. Lodha is Chairman of Audit Committee. He is also a member of NRC and Stakeholders Relationship Committee of the Company.

During his current tenure as an Independent Director of the Company, he has contributed immensely to the Board and Committee deliberations. The attendance of Mr. Lodha at Board and existing Committee meetings, since his appointment, is as follows:

Financial Year	Board Meeting			Audit Committee*			Nomination and Remuneration Committee			Stakeholders Relationship Committee		
	Total meetings held during tenure	Meetings attended	% of attendance	Total meetings held during tenure	Meetings attended	% of attendance	Total meetings held during tenure	Meetings attended	% of attendance	Total meetings held during tenure	Meetings attended	% of attendance
2023-24	8	8	100	8	8	100	3 [#]	3	100	3 [#]	3	100
2022-23	8	8	100	8	8	100	4 [#]	4	100	1 [#]	1	100
2021-22	8	8	100	7	7	100	4	4	100	Not Applicable		
2020-21	6	6	100	8	8	100	6	6	100	Not Applicable		
2019-20	4	3	75	5 [#]	4	80	3 [#]	2	66.67	Not Applicable		

*The Board constituted a separate Risk Management Committee on October 29, 2023 and accordingly, the nomenclature of 'Audit and Risk Management Committee' was changed to 'Audit Committee' w.e.f. October 29, 2023.

[#]The details of changes in the Committee(s) membership/ chairmanship of Mr. Lodha during this period, are as follows:

- a) Ceased to be member of Nomination and Remuneration Committee w.e.f. September 30, 2022. Subsequently, Mr. Lodha was inducted as member of Nomination and Remuneration Committee w.e.f. October 29, 2023.
- b) Inducted as Chairman and member of Stakeholders Relationship Committee w.e.f. September 30, 2022. Subsequently, upon reconstitution of Stakeholders Relationship Committee by Board, Mr. Lodha ceased to be Chairman and continued as member w.e.f. May 16, 2023.
- c) Upon appointment, he was inducted as member and chairman of Audit Committee and member of Nomination and Remuneration Committee w.e.f. June 21, 2019.

Brief profile:

“Mr. Lodha is a Chartered Accountant and a Law graduate with more than 41 years of experience in investment banking, corporate restructuring and corporate and project finance. He is on the board of companies such as Amul Exim Limited, Nitrex Chemicals India Limited, Parixit Irrigation Limited, Jaihind Projects Limited, Elate Investment and Holdings Private Limited, Sirius Financial Services Private Limited, Disha Infin Consultants Pvt Limited, Rasna Processors Private Limited and Rajdhani Textiles Private Limited and was earlier on the Board of Arvind Products Limited and Shyam Cotsyn India Limited.”

The profile of Mr. Lodha can also be accessed on Company's website viz. www.maxhealthcare.in/investors.

Proposal and rationale for re-appointment of Mr. Lodha

The Company follows a robust process for re-appointment of Board members. NRC oversees the succession planning, *inter-alia*, for the Board and thoroughly assesses various factors while considering re-appointment of Independent Director including background, expertise, skill set, experience, performance evaluation, educational & professional qualifications and personal achievements.

Further, the Board also deliberates on various factors including present composition of the Board to ensure optimum combination of executive and non-executive directors, tenure of the Board members, skill matrix, board diversity, time-commitment and statutory requirements.

During review process of succession planning on March 18, 2024, NRC, *inter-alia*, evaluated re-appointment of existing Independent Directors and considered the proposal for re-appointment of Mr. Lodha as an Independent Director on Company's Board.

Mr. Lodha has extensive experience of over four decades with expertise across industries in the fields of mergers & acquisitions, corporate restructuring, business turnaround and strategy, investment banking, corporate finance, as well as corporate governance and risk management. His strong leadership and business acumen are evidenced by several successful acquisition deals and business transformations showcasing his ability to identify potential opportunities, develop acquisition strategies, integrate businesses and turn around operations. Mr. Lodha's invaluable insights, particularly on governance, risk assurance and mitigation, have provided strategic guidance to the Company during its turnaround and growth journey. Mr. Lodha's multifaceted skillset, coupled with his extensive industry experience, continue to position him as a catalyst for driving sustained growth and shareholder value for the Company.

Mr. Lodha is deeply engaged in Company's strategies/ goals and actively contributes to Board and Committee meetings. As evident from the information provided above, he has maintained an excellent record at Board and Committee meetings. Leveraging his rich and extensive experience, interactions with Mr. Lodha provide invaluable mentorship to the Company's management team.

NRC, after taking into account the positive outcome of the performance evaluation of Mr. Lodha during his current term as an Independent Director and considering his skills, business acumen, knowledge, time commitment to Company, experience and expertise in mergers & acquisitions as well as his contribution to the Company's evolution as an industry leader and one of India's largest healthcare providers, recommended his re-appointment to the Board for a second term effective from June 21, 2024 to June 20, 2029. NRC further noted that skills, expertise and competencies possessed by Mr. Lodha are in alignment with the skills and expertise identified by the NRC and the Board, for the Directors of the Company.

The Board, at its meeting held on March 19, 2024, considered the recommendation of the NRC and comprehensive performance evaluation report of Mr. Lodha. The Board duly recognized Mr. Lodha's remarkable skills, deep understanding and rich experience in mergers & acquisitions, business transformation, compliance and assurance. In view of his contribution over years as an Independent Director of the Company, the Board believes that Mr. Lodha's continued association as an Independent Director would be of immense benefit during this pivotal phase of growth.

In order to comply with the requirements of the Act and SEBI Listing Regulations in letter & spirit, and as measure to uphold high standards on corporate governance, the Board concluded that the tenure (current and prospective) of all Independent Directors, including Mr. Lodha, should be considered from the date of their respective joining at Board of the Company. Accordingly, in line with the above and subject to approval of members of the Company, the Board approved the re-appointment of Mr. Lodha as an Independent Director of the Company for a second term of 5 (five) years up to June 20, 2029 i.e., the date when Mr. Lodha completes his 10 years association with the Company as Director. The re-appointment of Mr. Lodha is in accordance with the nomination, remuneration and board diversity policy of the Company.

Performance Evaluation

The Board, in consultation with NRC, had formulated a framework containing the criteria for performance evaluation of the entire Board, its Committees, Chairman and Individual Directors, including Independent Directors. NRC and the Board while considering performance evaluation of Mr. Lodha, *inter-alia*, considered assessment of his independent judgement that contributes to Board's deliberations, strategy and performance, his understanding of Company's business and goals, confidentiality, adherence to legal obligations and Company's code of conduct along with his understanding of roles and responsibilities as an Independent Director.

The NRC and Board are of the opinion that Mr. Lodha possesses relevant expertise and experience and is independent of management which duly fulfils the conditions specified in the Act, Rules made there under and SEBI Listing Regulations for re-appointment as an Independent Director.

Remuneration

Mr. Lodha shall be entitled to remuneration of ₹35,00,000/- (Rupees Thirty-Five Lakh only) per annum (payable on monthly basis) as approved by members of the Company in their

22nd Annual General Meeting held on September 27, 2023 or any other remuneration as may be approved by members of the Company from time to time on the recommendation of Board and NRC. The remuneration is in line with the existing remuneration being paid to all other Non-Executive Directors (including Independent Directors).

In addition to the aforesaid remuneration, Mr. Lodha shall also be entitled to sitting fees for attending meeting(s) of the Board or any Committee and reimbursement of the expenses for attending meetings of the Board and Committee thereof, as permissible under the Act and/or SEBI Listing Regulations.

Disclosures and confirmations

The Company has received the notice under section 160 of the Act from a member signifying candidature of Mr. Lodha for the office of directors of the Company.

The Company has also received following documents from Mr. Lodha:

- a) consent in writing to act as director in Form DIR-2;
- b) intimation in Form DIR-8 to the effect he is not disqualified from being re-appointed as a director in terms of section 164 of the Act;
- c) declaration to the effect that he meets the criteria of independence as under the Act and SEBI Listing Regulations;
- d) confirmation that he is neither disqualified nor debarred from holding the office of director under the Act or pursuant to any order issued by SEBI or any such other authority;

- e) confirmation that he is not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact his ability to discharge duties with an objective independent judgment and without any external influence; and
- f) confirmation that he is registered with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs in accordance with the Act.

The copy of draft letter for re-appointment of Mr. Lodha as Independent Director setting out the terms and conditions is available for electronic inspection to the members. The members may follow the process for inspection of document as mentioned in 'Notes' section forming part of the Notice.

The details as required under the SEBI Listing Regulations and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India and all other applicable provisions are provided in **Annexure** to the explanatory statement.

The Board recommends the resolution as set out in item no. 2 for approval of the members as special resolution.

Except Mr. Lodha and his relatives to the extent of their shareholding, if any, in the Company, none of the other directors / key managerial personnel and their relatives are in any way, concerned or interested, financially or otherwise, in the said resolution.

Registered Office

401, 4th Floor, Man Excellenza,
S. V. Road, Vile Parle (West),
Mumbai - 400 056, Maharashtra

By order of the Board of Directors
For **Max Healthcare Institute Limited**

Dhiraj Aroraa
SVP - Company Secretary & Compliance Officer

Membership No.: A28079

March 19, 2024
Gurugram

Details of Directors seeking Appointment
[Pursuant to Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings]

Name of Director	Mr. Michael Thomas Neeb	Mr. Mahendra Gumanmalji Lodha		
Director Identification Number (DIN)	08522685	00012920		
Age (years)	61 years	67 years		
Nationality	American	Indian		
Date of first appointment on the Board of the Company	June 21, 2019	June 21, 2019		
Expertise in specific functional areas/ experience	Refer to the Explanatory Statement of item no. 1 & 2			
Brief Resume	Refer to the Explanatory Statement of item no. 1 & 2			
Qualification	# Master of Business Administration from the University of Dallas	# Chartered Accountant		
	# Bachelor's degree in accounting from Baylor University	# Law Graduate		
No. of Board Meetings attended during FY 2023-24 and up to the date of Notice	7 of 8	8 of 8		
List of Directorship of other Board	# Listed Companies: None	# Listed Companies: None		
	# Unlisted Companies: None	# Unlisted Companies:		
	# Overseas Entities:	a) Amul Exim Limited		
	a) Evergreen Executive Advisors LLC	b) Nitrex Chemicals India Limited		
	b) Telemetrix RPM, Inc	c) Parixit Irrigation Limited		
		d) JaiHind projects limited		
		e) Elate Investment and Holdings Private Limited		
		f) Sirius Financial Services Private Limited		
		g) Disha Infin Consultants Private Limited		
		h) Rasna Processors Private Limited		
	i) Rajdhani Textiles Private Limited			
	# Overseas Entities: None			
List of Membership / Chairpersonship of Committees of other Board	None	Name of the Companies in which committee Memberships held	Name of the committee	Relation
			Audit Committee	Chairman
		Nitrex Chemicals India Limited	Corporate Social Responsibility Committee	Chairman
			Nomination and Remuneration Committee	Chairman
Listed entities from which the person has resigned in the past 3 years	None			
No. of shares held in the Company including shareholding as beneficial owner	Nil			
Relationship with other directors, managers and key managerial personnel	None			
Terms and Conditions of appointment	Refer to the Explanatory Statement of item no. 1 & 2			
Details of remuneration drawn (upto February 29, 2024)	₹27,58,333/-			
Details of remuneration sought to be paid	Refer to the Explanatory Statement of item no. 1 & 2			